Literature DB >> 18268269

Mortality benefit from unrestricted access to clopidogrel: too good to be true?

Samy Suissa1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18268269      PMCID： PMC2228354          DOI： 10.1503/cmaj.071592

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Clopidogrel and percutaneous coronary intervention.

Authors:  Christopher Cannon
Journal:  Lancet       Date:  2002-01-12       Impact factor: 79.321

2.  Clopidogrel and percutaneous coronary interventions.

Authors:  Robin P Choudhury
Journal:  JAMA       Date:  2003-04-16       Impact factor: 56.272

3.  Clopidogrel and percutaneous coronary interventions.

Authors:  John F P Bridges
Journal:  JAMA       Date:  2003-04-16       Impact factor: 56.272

4.  Immortal time bias in observational studies of drug effects.

Authors:  Samy Suissa
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-03       Impact factor: 2.890

5.  Restrictive access to clopidogrel and mortality following coronary stent implantation.

Authors:  Odile Sheehy; Jacques LeLorier; Stéphane Rinfret
Journal:  CMAJ       Date:  2008-02-12       Impact factor: 8.262
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.